{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:07:58Z","timestamp":1791389278324,"version":"4.3.3"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703124, 82173402"],"award-info":[{"award-number":["81703124, 82173402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Netherton syndrome is a rare, life-threatening autosomal recessive genetic disorder with no effective treatment yet. Skin barrier dysfunction caused by\n                      <jats:italic>SPINK5<\/jats:italic>\n                      gene mutations is a hallmark of the disease. Antigen penetration through the defective skin and nonspecific inflammation provide a pro-T helper 2 (Th2) immune microenvironment in the disease. Therefore, Th2 cytokines are considered to be candidate therapeutic targets.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical responses of patients with Netherton syndrome to dupilumab, an IL-4R\u03b1 antagonist, and identify changes in the Th1\/2\/17 pathway activity, skin barrier defect protein LEKTI expression after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four children with severe Netherton syndrome (aged 2 y to 4 y and 6\u00a0m) who were treated with dupilumab from January to June 2022 were evaluated at baseline, and at 4, 8, 12, 16, and 20 weeks after the start of dupilumab administration. Treatment response was assessed using the Eczema Area and Severity Index (EASI), the Numerical Rating Scale (NRS), the Dermatology Life Quality Index (CDLQI), and the Dermatitis Family Impact-questionnaire (DFI). Blood eosinophil counts, serum IgE levels and inflammatory cytokines were measured. The immunotyping of Th1\/2\/17 cells was performed by flow cytometry and cytokine expressions in T cell subsets were analyzed by single-cell RNA sequencing. In addition, expression of the LEKTI in skin lesions was evaluated by immunohistochemical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All four patients experienced clinical improvement, with significantly reduced EASI scores (by 75.0\u201383.9%) and NRS (by 87.5\u201390.0%) from baseline to 20 weeks of treatment. Improved quality of life scores were also seen for all patients, as measured by CDLQI and DFI. Serum IgE levels also fell by 75.6\u201386.9%. The serum Th2 cytokines IL-4, IL-5 and IL-13 were found at low level, with no significant changes during the treatment. However, Th2 cytokines expressed by T cells, especially IL-4, decreased at single-cell level after treatment (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.029). The baseline percentage of Th2 cells (among total CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells) was significantly higher in patients than that in healthy controls (HC) (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001); this percentage fell from 8.25% \u00b1 0.75% to 4.02% \u00b1 0.62% after 20 weeks dupilumab treatment. There was no noticeable change in LEKTI protein expression in skin lesions pre- and post-treatment. Two patients reported mild ocular adverse effects, but there were no severe adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab may be an effective and safe treatment option in a subset of pediatric patients with Netherton syndrome, especially in improving itch and the quality of life. These effects were achieved in part by suppression of the Th2-mediated inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1054422","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T08:35:47Z","timestamp":1670488547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation"],"prefix":"10.3389","volume":"13","author":[{"given":"Shi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuege","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/21678707.2020.1857724","article-title":"Advances in understanding of netherton syndrome and therapeutic implications","volume":"8","author":"Petrova","year":"2020","journal-title":"Expert Opin Orphan Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.11.007","article-title":"Netherton syndrome: Insights into pathogenesis and clinical implications","volume":"140","author":"Chiticariu","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.06.007","article-title":"Physiological and pathological roles of kallikrein-related peptidases in the epidermis","volume":"95","author":"Kishibe","year":"2019","journal-title":"J Dermatol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864449","article-title":"Outcomes of systemic treatment in children and adults with netherton syndrome: A systematic review","volume":"13","author":"Nouwen","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of netherton syndrome with dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14317","article-title":"Successful treatment with dupilumab of an adult with netherton syndrome","volume":"45","author":"Andreasen","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14362","article-title":"Netherton syndrome: Temporary response to dupilumab","volume":"37","author":"Aktas","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/children9030310","article-title":"Dupilumab improves pruritus in netherton syndrome: A case study","volume":"9","author":"Inaba","year":"2022","journal-title":"Children (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.03.003","article-title":"Successful dupilumab treatment for ichthyotic and atopic features of netherton syndrome","volume":"102","author":"Murase","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16883","article-title":"Response to dupilumab in two children with netherton syndrome: Improvement of pruritus and scaling","volume":"35","author":"S\u00fc\u00dfmuth","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16253","article-title":"Successful treatment of netherton syndrome with dupilumab: A case report and review of the literature","volume":"49","author":"Wang","year":"2022","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00441-013-1558-1","article-title":"Netherton syndrome: skin inflammation and allergy by loss of protease inhibition","volume":"351","author":"Hovnanian","year":"2013","journal-title":"Cell Tissue Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.024","article-title":"Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses","volume":"149","author":"Barbieux","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1019","article-title":"Secukinumab therapy for netherton syndrome","volume":"156","author":"Luchsinger","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Com\u00e8l-netherton syndrome defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017739","article-title":"IL-21 and IL-6 are critical for different aspects of b cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation","volume":"6","author":"Eto","year":"2011","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155828","article-title":"Interleukin-8: An evolving chemokine","volume":"153","author":"Matsushima","year":"2022","journal-title":"Cytokine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1054422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T08:35:52Z","timestamp":1670488552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1054422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2022.1054422"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1054422","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1054422"}}